Symbols

CAPR

Capricor·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

Significant Net Income Decline

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CAPR

Capricor Therapeutics, Inc.

A company that developing regenerative medicine and large molecule products to treat heart failure

Industry

Biological Technology

Established Date

Listing Date

03/09/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

231

Fiscal Year Ends

12-31

Website

www.capricor.com

Security Type

Common stock

Office address

10865 Road to the Cure, Suite 150, San Diego, California 92121

Business

Introduction

Capricor Therapeutics, Inc., is incorporated in Delaware. The company is a biotechnology company focused on the development of cell and exosome therapies for the treatment of Duchenne muscular dystrophy. Its lead drug candidate, Deramiocel, is a cell therapy currently under FDA review for the treatment of cardiac and skeletal muscle complications of DMD.

Company Financials

EPS

CAPR has released its 2025 Q4 earnings. EPS was reported at -0.62, versus the expected -0.51, missing expectations. The chart below visualizes how CAPR has performed over recent quarters, highlighting trends in earnings surprises.